<DOC>
	<DOCNO>NCT02216552</DOCNO>
	<brief_summary>The current project design 30-day pilot trial demonstrate safety tolerability resveratrol therapy overweight adolescent decrease liver fat , improve insulin sensitivity prevent type 2 diabetes .</brief_summary>
	<brief_title>Resveratrol Treatment Non Alcoholic Fatty Liver Disease Insulin Resistance Overweight Adolescents</brief_title>
	<detailed_description>Pilot study 10 overweight obese child MRS determine fatty liver randomize resveratrol placebo . Primary outcome measure include change liver triglyceride content determine MRS improvement insulin resistance determine area curve glucose excursion 75 gram oral glucose tolerance test .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Resveratrol</mesh_term>
	<criteria>13 &lt; 18 year age BMI consider overweight ( BMI &gt; 25 kg/m2 ) obese ( BMI &gt; 30 kg/m2 ) Confirmed 1HMRS define hepatic steatosis ( &gt; 5.5 % fat/water ) Parent/Guardian willing able provide write , sign informed consent , subject willing cosign parental consent Sexually active subject must willing use acceptable method contraception Females child bear potential must negative pregnancy test screening . The use chronic medication exception oral birth control natural health product exception multivitamin . Adolescents alter insulin sensitivity tissue lipid content unrelated obesity metabolic syndrome , include : type 2 diabetes ; present previous malignancy renal disease , hypertension ( anyone BPs 99th percentile age gender ) liver disease ; significant weight loss ( 10 % last six month ) enrol weight loss program six month prior study ; selfreported history alcohol consumption great two drink per day and/or drink alcohol weekly ; report use nonprescription recreational drug ; allergy sensitivities ingredient investigational product placebo ; female breastfeed screen plan become pregnant time study ;</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pediatrics</keyword>
	<keyword>Adolescents</keyword>
	<keyword>NAFLD</keyword>
	<keyword>Spectroscopy</keyword>
	<keyword>Type 2 diabetes</keyword>
</DOC>